Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 12, 2025 | – | $1.07 | |
| Aug 7, 2025 | -$0.12 | -$0.12 | Beat |
| May 13, 2025 | -$0.12 | -$0.22 | Miss |
| Mar 31, 2025 | -$0.16 | -$0.42 | Miss |
| Nov 7, 2024 | -$0.31 | -$0.31 | Beat |
| Aug 8, 2024 | -$0.36 | -$0.27 | Beat |